Clinical Trial Update: Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated weekly subcutaneous semaglutide as an adjunct to closed-loop therapy in people with Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 2, Phase 3 | Status: COMPLETED